Teva Pharmaceutical Industries Sued by Corcept Over Korlym Generic Labeling

Teva faces legal fight over Korlym generic labeling

Teva Pharmaceutical Industries is defending a challenge from Corcept Therapeutics over the proposed label for Teva’s generic version of Korlym, a drug used to treat Cushing’s syndrome. Corcept alleges the label would effectively induce physicians to follow a patented dosing regimen that pairs the active ingredient mifepristone with potent CYP3A inhibitors such as ketoconazole, and is seeking court intervention to prevent what it calls inducement of patent infringement. The dispute centers on whether label language that describes co‑administration, dosing relationships or management of drug exposure can be treated as directing clinical practice in a way that breaches Corcept’s method‑of‑use patents.

At issue are the boundaries among regulatory labeling, physician prescribing behavior and method patent rights, where small differences in wording can shape how a medicine is used in practice. Corcept contends that Teva’s proposed instructions would steer clinicians toward the specific combinations and dosing relationships claimed in its patents, creating a risk of third‑party infringement even if the generic product is chemically identical. Teva argues that regulatory approval of a generic with an appropriate label is lawful and that the label should reflect safe, effective use without enabling patented methods, with the ultimate interpretation turning on court and regulatory rulings now pending.

The outcome has broader implications for generic approvals and how companies write labels when method patents exist, with potential consequences for patient access and the balance of incentives for drug innovation. If courts accept Corcept’s inducement theory, manufacturers and regulators may face tighter constraints on labeling language, potentially complicating generic entry for drugs where downstream prescribing decisions intersect with method patents. Regulators’ assessments and judicial clarification will determine whether Teva’s label changes prescribing practice as Corcept predicts and whether patients gain a lower‑cost alternative.

Wall Street attention remains active as analysts continue to scrutinize Teva’s legal, regulatory and pipeline dynamics. Thirteen analysts review the company in the most recent quarter, producing divergent views that highlight uncertainty over drug competition, patent exposure and Teva’s strategic responses, though these assessments primarily inform market expectations rather than the legal question before the courts.

Industry observers say the case could set a precedent affecting how generics are labeled when method patents exist, and stakeholders including physicians, payers and patient groups are watching for decisions that will affect access to treatments and the incentives for developing novel dosing strategies.